Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 May;11(7):1215-23.
doi: 10.1517/14656561003801081.

Treatment of HIV infection with the CCR5 antagonist maraviroc

Wiete Kromdijk  1 , Alwin D R Huitema, Jan Willem Mulder
Affiliations
Review

Treatment of HIV infection with the CCR5 antagonist maraviroc

Wiete Kromdijk et al. Expert Opin Pharmacother. 2010 May.

Abstract

Importance of the field: The emergence of resistance in treatment-experienced HIV patients often limits therapeutic success of the currently available antiretroviral drugs. New drug classes are thus required. Maraviroc is the first chemokine receptor 5 antagonist approved for use in treatment experienced HIV patients with a R5-tropic virus.

Areas covered in this review: For this review, data from pharmacokinetic, Phase II and III clinical trials were reviewed.

What the reader will gain: The objectives of this review were to discuss the pharmacokinetics and clinical efficacy and safety of maraviroc in treatment-experienced and -naive HIV patients with R5-tropic virus. Additionally, tropism testing was discussed.

Take home message: Maraviroc is effective in previously treated patients with R5-tropic virus only. Also, maraviroc will be an attractive option for HIV-1-infected treatment-naive patients with R5-tropic viruses only, once genotypic assays have been validated.

PubMed Disclaimer

MeSH terms

LinkOut - more resources